Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02629159 · ClinicalTrials.gov registry record · Phase 3
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate
A Phase 3 study of Rheumatoid Arthritis, sponsored by AbbVie.
- Active
- Registry status
- Phase 3
- Development phase
- 1,629
- Enrollment target
- 20
- Study locations
NCT02629159 is a Phase 3 study of Rheumatoid Arthritis that is active but no longer recruiting, run by AbbVie. The registered enrollment target is 1,629 participants, below the 4,682-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (65% lower). The trial reports 20 study locations across 3 states.
The verdict
NCT02629159, a Phase 3 study of Rheumatoid Arthritis, is active but no longer recruiting, sponsored by AbbVie.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,629 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study was to assess efficacy, including inhibition of radiographic progression, and safety with upadacitinib versus placebo and versus an active comparator, adalimumab, in adults with with moderately to severely active rheumatoid arthritis (RA) who are on a stable background of methotrexate (MTX and who have an inadequate response to MTX.
Conditions Studied
Interventions
- DRUG Adalimumab
- DRUG Upadacitinib
- DRUG Placebo for Upadacitinib
- DRUG Placebo for Adalimumab
Study Locations (20)
California
- Osteoporosis Medical Center /ID# 153935 - Beverly Hills
- T. Joseph Raoof, MD, Inc. /ID# 144884 - Encino
- Rheumatology Ctr of San Diego /ID# 153747 - Escondido
- C.V. Mehta MD, Med Corporation /ID# 143116 - Hemet
- Allergy and Rheum Med Clin /ID# 146083 - La Jolla
- Kotha and Kotha /ID# 161046 - La Mesa
- TriWest Research Associates- La Mesa /ID# 143115 - La Mesa
- Valerius Med Grp & Res Ctr /ID# 143120 - Los Alamitos
- Discovery MM Services, Inc /ID# 163504 - Los Angeles
- Desert Medical Advances /ID# 143097 - Palm Desert
Arizona
- AZ Arthritis and Rheum Assoc /ID# 143130 - Mesa
- SunValley Arthritis Center, Lt /ID# 143123 - Peoria
- Elite Clinical Studies, LLC /ID# 144881 - Phoenix
- AZ Arthritis and Rheum Researc /ID# 143080 - Phoenix
- AZ Arthritis and Rheum Researc /ID# 143121 - Phoenix
- AZ Arthritis & Rheuma Research /ID# 143131 - Phoenix
- Arizona Research Center, Inc. /ID# 144877 - Phoenix
- AZ Arthritis & Rheum Research /ID# 156093 - Sun City
- University of Arizona Cancer Center - North Campus /ID# 143114 - Tucson
Alabama
- Achieve Clinical Research, LLC /ID# 143136 - Birmingham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,629 participants |
| Start Date | 2015-12-01 |
| Est. Completion | 2027-09-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02629159
The ClinicalTrials.gov registry entry for NCT02629159 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 1,629 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,682-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (65% lower). The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Rheumatoid Arthritis appearing as the primary indexed condition, and to 4 interventions - of which Adalimumab is the first listed.
NCT02629159 reports 20 study locations spanning 3 distinct geographic areas - top geographies include California, Arizona, Alabama.
Frequently Asked Questions
What is clinical trial NCT02629159 about?
NCT02629159 is a clinical study titled "A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate". The purpose of this study was to assess efficacy, including inhibition of radiographic progression, and safety with upadacitinib versus placebo and versus an active comparator, adalimumab, in adults with with moderately to severely active rheumatoid arthritis (RA) who are on a stable background of m...
What is the current status of trial NCT02629159?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 1,629 participants. The study started on 2015-12-01. Estimated completion is 2027-09-30.
What conditions does trial NCT02629159 study?
This clinical trial studies the following conditions: Rheumatoid Arthritis.
What interventions are being tested in trial NCT02629159?
The interventions under investigation include: Adalimumab (DRUG), Upadacitinib (DRUG), Placebo for Upadacitinib (DRUG), Placebo for Adalimumab (DRUG).
Who is sponsoring clinical trial NCT02629159?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02629159 being conducted?
This trial has 20 study locations across Alabama, Arizona, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Rheumatoid Arthritis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response
RECRUITING · Phase 3
-
Ra-pro Pragmatic Trial
RECRUITING · Phase 3
-
Vagus Nerve Stimulation for Moderate to Severe Rheumatoid Arthritis
ACTIVE NOT RECRUITING · Phase 3
-
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Compare the Response to Treatment With Abatacept vs Adalimumab, on Background Methotrexate, in Adults With Early, Seropositive, and Shared Epitope-positive Rheumatoid Arthritis and an Inadequate Response to Methotrexate
ACTIVE NOT RECRUITING · Phase 3
-
A Study in Participants With Moderate to Severe Rheumatoid Arthritis
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.